Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac.
International audienceA meningococcal B:14:P1.7,16 outbreak in Normandy (France) was recently controlled using MenBvac, an outer membrane vesicle vaccine previously designed against the B:15:P1.7,16 strain. The further emergence of a new B:14:P1.7,16 outbreak in another district in Normandy led us to explore immunity against B:14:P1.7,16 before and after the MenBvac campaign using a 2+1 (day 0, week 6, month 8) schedule. Children (1-5 years) were sampled before, during and up to one year after vaccination. Serum bactericidal activity against B:14:P1.7,16 was titrated using human complement (hSBA) and immune response was defined by hSBA titer ≥4 as a surrogate for protection. The percentage of hSBA titer ≥4 was 10.8% before vaccination, raised to 84.1% 6 weeks after the completion of the schedule, but declined to 39.7% one year later. This level is lower than the targeted 60% level and suggests only short-term persistence of response against B:14:P1.7,16 using this schedule
Outer membrane vesicle vaccine, Immune response, Neisseria meningitidis, MESH: Antibodies, Bacterial, MESH: Bacterial Outer Membrane Proteins, MESH: Neisseria meningitidis, MESH: Serum Bactericidal Test, MESH: Child, Preschool, MESH: Complement System Proteins, MESH: France, MESH: Humans, MESH: Immunization Schedule, MESH: Infant, MESH: Meningococcal Infections, MESH: Meningococcal Vaccines, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Publisher: 'Elsevier BV'
DOI identifier: 10.1016/j.vaccine.2012.05.051
Sorry, we are unable to provide the full text but you may find it at the